## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

	OMB APPROVAL					
OMB Number: 3235-0						
	Estimated average bur	den				
	hours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person *- RODRIGUEZ RAUL R					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 02/02/2017							X Officer give title below) Other (specify below)  CEO, President					
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						es Acquire	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		Execution Date, if Code		4. Securities Acc (A) or Disposed (Instr. 3, 4 and 5)		of (D) Or Tr			١	Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
Reminder:	Report on a s	eparate line for each	n class of securities b	- Deriva	ative	e Securitie	s Acq	Persin thin a cur	ons is for rrer	s who respon form are not re ntly valid OME	equired to B control eficially Ov	o respond ι number.				1474 (9-02)
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Executor Exercise (Month/Day/Year) any			4. Transaction Code		<u> </u>		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5) Be Ov Fo Re		Owners Form of Derivati Security Direct (I or Indire	Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4	
Stock Option (Right to Buy)	\$ 2.11	02/02/2017		A		450,000	)	(1)		02/02/2027	Commo Stock	450,000	\$ 0	450,000	D	

### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
RODRIGUEZ RAUL R RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X		CEO, President		

#### **Signatures**

/s/ Dolly Vance (Attorney-in-Fact)	02/06/2017
Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over four (4) years from January 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.